KR20240124921A - 약학적 조성물 및 이의 용도 - Google Patents

약학적 조성물 및 이의 용도 Download PDF

Info

Publication number
KR20240124921A
KR20240124921A KR1020247020083A KR20247020083A KR20240124921A KR 20240124921 A KR20240124921 A KR 20240124921A KR 1020247020083 A KR1020247020083 A KR 1020247020083A KR 20247020083 A KR20247020083 A KR 20247020083A KR 20240124921 A KR20240124921 A KR 20240124921A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
acceptable salt
furmonatinib
mutation
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020083A
Other languages
English (en)
Korean (ko)
Inventor
후이빙 루오
칭 리
Original Assignee
상하이 알리스트 파마슈티컬즈 씨오., 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 상하이 알리스트 파마슈티컬즈 씨오., 엘티디. filed Critical 상하이 알리스트 파마슈티컬즈 씨오., 엘티디.
Publication of KR20240124921A publication Critical patent/KR20240124921A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247020083A 2021-11-24 2022-11-21 약학적 조성물 및 이의 용도 Pending KR20240124921A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111404293.6A CN116159062A (zh) 2021-11-24 2021-11-24 药物组合物及其用途
CN202111404293.6 2021-11-24
PCT/CN2022/133171 WO2023093663A1 (en) 2021-11-24 2022-11-21 Pharmaceutical composition and use thereof

Publications (1)

Publication Number Publication Date
KR20240124921A true KR20240124921A (ko) 2024-08-19

Family

ID=86416859

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020083A Pending KR20240124921A (ko) 2021-11-24 2022-11-21 약학적 조성물 및 이의 용도

Country Status (10)

Country Link
US (1) US20250017927A1 (https=)
EP (1) EP4436580A4 (https=)
JP (1) JP2024539476A (https=)
KR (1) KR20240124921A (https=)
CN (2) CN116159062A (https=)
AU (1) AU2022397653A1 (https=)
CA (1) CA3238480A1 (https=)
IL (1) IL312874A (https=)
MX (1) MX2024006168A (https=)
WO (1) WO2023093663A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116854694B (zh) * 2023-07-04 2024-07-09 北京浦润奥生物科技有限责任公司 [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105315259B (zh) * 2014-07-29 2018-03-09 上海艾力斯医药科技有限公司 吡啶胺基嘧啶衍生物、其制备方法及应用
MX2022007969A (es) * 2019-12-23 2022-12-13 Blueprint Medicines Corp Inhibidores de egfr.
WO2023035223A1 (zh) * 2021-09-10 2023-03-16 上海艾力斯医药科技股份有限公司 药物组合物及其用途
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof

Also Published As

Publication number Publication date
IL312874A (en) 2024-07-01
JP2024539476A (ja) 2024-10-28
CN118678958A (zh) 2024-09-20
EP4436580A1 (en) 2024-10-02
MX2024006168A (es) 2024-06-11
CA3238480A1 (en) 2023-06-01
US20250017927A1 (en) 2025-01-16
WO2023093663A1 (en) 2023-06-01
AU2022397653A1 (en) 2024-07-04
CN116159062A (zh) 2023-05-26
EP4436580A4 (en) 2025-09-24

Similar Documents

Publication Publication Date Title
WO2023035611A1 (en) Pharmaceutical composition and use thereof
US20180353602A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
AU2020279289B2 (en) Quinoline derivative used for combination treatment of small cell lung cancer
US20250017927A1 (en) Pharmaceutical composition and use thereof
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
CN112121048A (zh) 用于联合治疗食管癌的喹啉类化合物
WO2024061203A1 (en) Pharmaceutical composition and use thereof
JP7571053B2 (ja) 軟部肉腫の併用療法用キノリン誘導体
CN112043832A (zh) 用于联合治疗胃癌的喹啉类化合物
EP3973963A1 (en) Quinoline derivatives for treatment of head and neck cancer
HK40116696A (zh) 药物组合物及其用途
HK40110967A (zh) 药物组合物及其用途
HK40072142A (en) Quinoline derivative used for combination treatment of small cell lung cancer
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000